$RARE
Ultragenyx Pharmaceutical Inc. Stock $rare

$rare Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000095017022013411 Filed on July 29, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$90.70M	$89.34M	$79.94M
YoY Change	11.09%	2.72%	-19.58%
Cost Of Revenue	$8.631M	$8.270M	$6.100M
YoY Change	106.73%	163.71%	17.53%
Gross Profit	$82.07M	$81.07M	$73.84M
YoY Change	5.94%	-3.3%	-21.63%
Gross Profit Margin	90.48%	90.74%	92.37%
Selling, General & Admin	$69.84M	$68.14M	$67.31M
YoY Change	29.62%	27.57%	26.39%
% of Gross Profit	85.1%	84.04%	91.17%
Research & Development	$237.3M	$154.5M	$143.2M
YoY Change	109.23%	36.5%	-2.96%
% of Gross Profit	289.13%	190.6%	193.89%
Depreciation & Amortization	$4.694M	$4.481M	$4.088M
YoY Change	45.91%	43.71%	21.41%
% of Gross Profit	5.72%	5.53%	5.54%
Operating Expenses	$307.1M	$222.7M	$210.5M
YoY Change	83.59%	33.64%	4.83%
Operating Profit	-$225.1M	-$141.6M	-$136.6M
YoY Change	150.55%	71.06%	28.21%
Interest Expense	$1.857M	-$9.285M	-$8.835M
YoY Change	-92.89%	-69.66%	-55.78%
% of Operating Profit
Other Income/Expense, Net	-$1.105M	-$930.0K	$289.0K
YoY Change	166.27%	1288.06%	-136.35%
Pretax Income	-$238.8M	-$157.9M	-$151.8M
YoY Change	227.98%	29.43%	11.79%
Income Tax	$6.287M	$302.0K	$558.0K
% Of Pretax Income
Net Earnings	-$245.1M	-$158.2M	-$152.3M
YoY Change	235.77%	29.19%	11.88%
Net Earnings / Revenue	-270.23%	-177.03%	-190.55%
Basic Earnings Per Share	-$3.50	-$2.26	-$2.19
Diluted Earnings Per Share	-$3.50	-$2.262M	-$2.191M
COMMON SHARES
Basic Shares Outstanding	70.04M	69.93M	69.38M
Diluted Shares Outstanding	70.05M	69.93M	69.52M

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$888.7M	$542.8M	$598.3M
YoY Change	20.56%	-35.82%	-38.02%
Cash & Equivalents	$391.7M	$159.9M	$154.0M
Short-Term Investments	$497.0M	$382.9M	$444.3M
Other Short-Term Assets	$70.98M	$77.46M	$63.02M
YoY Change	2.58%	21.16%	-7.32%
Inventory	$21.85M	$21.08M	$17.81M
Prepaid Expenses
Receivables	$31.16M	$37.21M	$28.37M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.013B	$678.5M	$707.5M
YoY Change	19.58%	-28.54%	-33.93%
LONG-TERM ASSETS
Property, Plant & Equipment	$234.6M	$207.4M	$177.1M
YoY Change	97.04%	44.83%	40.42%
Goodwill	$44.41M	$44.41M	$44.41M
YoY Change	0.0%
Intangibles	$158.4M	$159.2M	$160.0M
YoY Change	21.04%
Long-Term Investments	$121.3M	$178.7M	$241.1M
YoY Change	-58.22%	-22.88%	11.42%
Other Assets	$18.29M	$21.14M	$21.22M
YoY Change	11.36%	66.91%	138.4%
Total Long-Term Assets	$605.8M	$642.1M	$676.5M
YoY Change	-5.03%	14.06%	28.39%
TOTAL ASSETS
Total Short-Term Assets	$1.013B	$678.5M	$707.5M
Total Long-Term Assets	$605.8M	$642.1M	$676.5M
Total Assets	$1.618B	$1.321B	$1.384B
YoY Change	9.0%	-12.68%	-13.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$23.53M	$34.21M	$23.69M
YoY Change	51.09%	57.01%	50.86%
Accrued Expenses	$189.1M	$170.4M	$126.4M
YoY Change	72.4%	87.08%	52.79%
Deferred Revenue		$4.437M	$5.867M
YoY Change		13.42%	-76.62%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$227.4M	$220.6M	$167.2M
YoY Change	67.26%	73.64%	31.68%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$4.050M	$3.768M	$3.392M
YoY Change	759.87%	-99.01%	-99.11%
Total Long-Term Liabilities	$4.050M	$3.768M	$3.392M
YoY Change	759.87%	-99.01%	-99.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$227.4M	$220.6M	$167.2M
Total Long-Term Liabilities	$4.050M	$3.768M	$3.392M
Total Liabilities	$1.150B	$642.6M	$587.6M
YoY Change	108.6%	18.93%	8.17%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.629B	-$2.384B	-$2.226B
YoY Change	34.75%
Common Stock	$70.00K	$70.00K	$70.00K
YoY Change	2.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$468.8M	$678.1M	$796.4M
YoY Change
Total Liabilities & Shareholders Equity	$1.618B	$1.321B	$1.384B
YoY Change	9.0%	-12.68%	-13.38%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$245.1M	-$158.2M	-$152.3M
YoY Change	235.77%	29.19%	11.88%
Depreciation, Depletion And Amortization	$4.694M	$4.481M	$4.088M
YoY Change	45.91%	43.71%	21.41%
Cash From Operating Activities	-$95.35M	-$77.26M	-$117.5M
YoY Change	59.84%	18.22%	-26.25%
INVESTING ACTIVITIES
Capital Expenditures	-$26.05M	-$30.92M	$32.18M
YoY Change	26.68%	54.04%	96.08%
Acquisitions
YoY Change
Other Investing Activities	-$135.8M	$110.1M	-$2.578M
YoY Change	572.37%	-619.91%	-98.45%
Cash From Investing Activities	-$161.9M	$79.17M	-$37.36M
YoY Change	297.11%	-291.92%	-79.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	491.9M	5.837M	1.612M
YoY Change	6414.93%	-53.77%	-87.26%
NET CHANGE
Cash From Operating Activities	-95.35M	-77.26M	-117.5M
Cash From Investing Activities	-161.9M	79.17M	-37.36M
Cash From Financing Activities	491.9M	5.837M	1.612M
Net Change In Cash	234.7M	7.748M	-153.4M
YoY Change	-352.72%	-108.24%	-53.51%
FREE CASH FLOW
Cash From Operating Activities	-$95.35M	-$77.26M	-$117.5M
Capital Expenditures	-$26.05M	-$30.92M	$32.18M
Free Cash Flow	-$69.30M	-$46.33M	-$149.7M
YoY Change	77.29%	2.33%	-14.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherNoncurrentAssetsMember
CY2021Q2	us-gaap	Restricted Cash And Cash Equivalents Current Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PrepaidExpenseAndOtherAssetsCurrent
	dei	Amendment Flag AmendmentFlag	false
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents Current Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsCurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PrepaidExpenseAndOtherAssetsCurrent
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001515673
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherNoncurrentAssetsMember
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36276
	dei	Entity Registrant Name EntityRegistrantName	ULTRAGENYX PHARMACEUTICAL INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-2546083
	dei	Entity Address Address Line1 EntityAddressAddressLine1	60 Leveroni Court
	dei	Entity Address City Or Town EntityAddressCityOrTown	Novato
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94949
	dei	City Area Code CityAreaCode	415
	dei	Local Phone Number LocalPhoneNumber	483-8800
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	RARE
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	70036868
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	159868000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	678542000
CY2022Q2	rare	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	358942000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	307584000
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	382927000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	432612000
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	37207000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28432000
CY2022Q2	us-gaap	Inventory Net InventoryNet	21079000
CY2021Q4	us-gaap	Inventory Net InventoryNet	16231000
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	77461000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	71745000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	856604000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	207381000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	141247000
CY2022Q2	rare	Equity Investments Noncurrent EquityInvestmentsNoncurrent	15412000
CY2021Q4	rare	Equity Investments Noncurrent EquityInvestmentsNoncurrent	34925000
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	163301000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	258933000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	31245000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	34936000
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	159196000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	130788000
CY2022Q2	us-gaap	Goodwill Goodwill	44406000
CY2021Q4	us-gaap	Goodwill Goodwill	44406000
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	21144000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20558000
CY2022Q2	us-gaap	Assets Assets	1320627000
CY2021Q4	us-gaap	Assets Assets	1522397000
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	34213000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17138000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	170355000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	145555000
CY2022Q2	rare	Contract Liabilities Current ContractLiabilitiesCurrent	4437000
CY2021Q4	rare	Contract Liabilities Current ContractLiabilitiesCurrent	7609000
CY2022Q2	rare	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	11631000
CY2021Q4	rare	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	11066000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	220636000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	181368000
CY2022Q2	rare	Contract Liabilities Noncurrent ContractLiabilitiesNoncurrent	0
CY2021Q4	rare	Contract Liabilities Noncurrent ContractLiabilitiesNoncurrent	1467000
CY2022Q2	rare	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	25902000
CY2021Q4	rare	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	30904000
CY2022Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	33306000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	33306000
CY2021Q4	rare	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	351786000
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3768000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1005000
CY2022Q2	us-gaap	Liabilities Liabilities	642554000
CY2021Q4	us-gaap	Liabilities Liabilities	599836000
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70010398
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70010398
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69344998
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69344998
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	70000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	69000
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3071000000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2997497000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8914000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1404000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2384083000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2073601000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	678073000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	922561000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1320627000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1522397000
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	89343000
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	86975000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	169278000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	186370000
CY2022Q2	rare	Cost Of Sales CostOfSales	8270000
CY2021Q2	rare	Cost Of Sales CostOfSales	3136000
	rare	Cost Of Sales CostOfSales	14370000
	rare	Cost Of Sales CostOfSales	8324000
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	154529000
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	113205000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	297684000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	260723000
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	68137000
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	53410000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	135449000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	106668000
CY2022Q2	rare	Cost Of Sales And Operating Expenses CostOfSalesAndOperatingExpenses	230936000
CY2021Q2	rare	Cost Of Sales And Operating Expenses CostOfSalesAndOperatingExpenses	169751000
	rare	Cost Of Sales And Operating Expenses CostOfSalesAndOperatingExpenses	447503000
	rare	Cost Of Sales And Operating Expenses CostOfSalesAndOperatingExpenses	375715000
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-141593000
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-82776000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-278225000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-189345000
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	899000
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	441000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1393000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1080000
CY2022Q2	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-10184000
CY2021Q2	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-31046000
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-19513000
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-51665000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	36188000
CY2022Q2	rare	Issuance Of Common Stock Under Equity Plan Awards Net Of Tax IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax	5983000
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2360000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-158162000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	678073000
CY2022Q2	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	6052000
CY2021Q2	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	8517000
	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	12636000
	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	16935000
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-930000
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-67000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-641000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-862000
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-157860000
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-121965000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-309622000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-257727000
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	302000
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	463000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	860000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	842000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-158162000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-122428000
	us-gaap	Net Income Loss NetIncomeLoss	-310482000
	us-gaap	Net Income Loss NetIncomeLoss	-258569000
CY2022Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.26
CY2021Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.81
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.45
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.84
CY2022Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	69925358
CY2021Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67607752
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	69722141
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67356443
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-158162000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-122428000
	us-gaap	Net Income Loss NetIncomeLoss	-310482000
	us-gaap	Net Income Loss NetIncomeLoss	-258569000
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-731000
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	103000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-791000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-182000
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1629000
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	73000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-6719000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-275000
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2360000
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	176000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-7510000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-457000
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-160522000
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-122252000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-317992000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-259026000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	796424000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	922561000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	65766000
	rare	Issuance Of Common Stock Under Equity Plan Awards Net Of Tax IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax	7738000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-7510000
	us-gaap	Net Income Loss NetIncomeLoss	-310482000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	678073000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	1054582000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	27099000
CY2021Q2	rare	Issuance Of Common Stock Under Equity Plan Awards Net Of Tax IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax	12742000
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	176000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-122428000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	972171000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1154375000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	51319000
	rare	Issuance Of Common Stock Under Equity Plan Awards Net Of Tax IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax	25503000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-457000
	us-gaap	Net Income Loss NetIncomeLoss	-258569000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	972171000
	us-gaap	Net Income Loss NetIncomeLoss	-310482000
	us-gaap	Net Income Loss NetIncomeLoss	-258569000
	rare	Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost AllocatedShareBasedCompensationExpenseNetOfCapitalizedInventoryCost	65260000
	rare	Allocated Share Based Compensation Expense Net Of Capitalized Inventory Cost AllocatedShareBasedCompensationExpenseNetOfCapitalizedInventoryCost	51345000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-3380000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-2511000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8569000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6488000
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-19513000
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-51665000
	rare	Non Cash Collaboration Royalty Revenue NonCashCollaborationRoyaltyRevenue	10261000
	rare	Non Cash Collaboration Royalty Revenue NonCashCollaborationRoyaltyRevenue	8561000
	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	12636000
	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties	16935000
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-386000
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-511000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8902000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1669000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4705000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2174000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6793000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9002000
	rare	Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherOperatingLiabilities	41260000
	rare	Increase Decrease In Accounts Payable Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherOperatingLiabilities	-11526000
	rare	Increase Decrease In Contract Liabilities IncreaseDecreaseInContractLiabilities	-4639000
	rare	Increase Decrease In Contract Liabilities IncreaseDecreaseInContractLiabilities	-62656000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-194778000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-224702000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	63107000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	36485000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	205278000
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	664347000
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	42950000
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	70548000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	297304000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	406614000
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	30000000
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	63000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	41806000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-223670000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	7738000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	25503000
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-289000
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-226000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7449000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25277000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1346000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-323000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-146869000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-423418000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	309585000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	726294000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	162716000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	302876000
	rare	Operating And Finance Lease Liability From Obtaining Right Of Use Assets OperatingAndFinanceLeaseLiabilityFromObtainingRightOfUseAssets	1036000
	rare	Operating And Finance Lease Liability From Obtaining Right Of Use Assets OperatingAndFinanceLeaseLiabilityFromObtainingRightOfUseAssets	2301000
	rare	Non Cash Interest Expense On Liability Related To The Sale Of Future Royalties Capitalized Into Ending Property Plant And Equipment NonCashInterestExpenseOnLiabilityRelatedToTheSaleOfFutureRoyaltiesCapitalizedIntoEndingPropertyPlantAndEquipment	4781000
	us-gaap	Nature Of Operations NatureOfOperations	<p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">1. Organization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Ultragenyx Pharmaceutical Inc. (the Company) is a biopharmaceutical company incorporated in Delaware.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company operates as </span><span style="font-size:10.0pt;font-family:Calibri;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"> reportable segment. The Company has four commercially approved products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Crysvita® (burosumab) is approved in the United States (U.S.) by the U.S. Food and Drug Administration (FDA) and in Canada for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients one year of age and older, and is approved in the European Union (EU) and the United Kingdom, for the treatment of XLH with radiographic evidence of bone disease in children one year of age and older, adolescents, and adults. In Brazil, Colombia, and Mexico, Crysvita is approved for treatment of XLH in adult and pediatric patients one year of age and older. Crysvita is also approved in the U.S. by the FDA for the treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia (TIO), associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adults and pediatric patients 2 years of age and older.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Mepsevii® (vestronidase alfa) is approved by the FDA as the first medicine for the treatment of children and adults with mucopolysaccharidosis VII (MPS VII), also known as Sly syndrome. In the European Union and the United Kingdom, Mepsevii is approved under exceptional circumstances for patients of all ages for the treatment of non-neurological manifestations of MPS VII. In Brazil, Mepsevii is approved for the treatment of MPS VII for patients of all ages.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Dojolvi® (triheptanoin) is approved in the U.S., Canada, and Brazil for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders (LC-FAOD).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">On January 7, 2022, the Company announced a collaboration with Regeneron Pharmaceuticals (Regeneron) to commercialize Evkeeza® (evinacumab) outside of the U.S. Evkeeza is approved in the U.S. and the European Economic Area (EEA) for the treatment of homozygous familial hypercholesterolemia (HoFH).</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">In addition to the approved products, the Company has the following ongoing clinical development programs:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"> </span></p><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:4.5pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">UX111 (formerly ABO-102) is an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A (MPS IIIA), a rare lysosomal storage disease. In May 2022, the Company announced an exclusive license agreement with Abeona Therapeutics Inc. (Abeona) for UX111 whereby the Company assumed responsibility for the UX111 program, as further described in Note 6;</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:4.5pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">DTX401 is an adeno-associated virus 8 (AAV8) gene therapy product candidate for the treatment of patients with glycogen storage disease type Ia (GSDIa);</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:4.5pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">DTX301 is an AAV8 gene therapy product candidate in development for the treatment of patients with ornithine transcarbamylase (OTC) deficiency, the most common urea cycle disorder;</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:4.5pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">UX143 (setrusumab), which is subject to the Company's collaboration agreement with Mereo BioPharma 3 (Mereo), is a fully human monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway and inhibits the activity of bone-forming cells for the treatment of patients with osteogenesis imperfect (OI); </span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:4.5pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">GTX-102 is an antisense oligonucleotide (ASO), which the Company is developing through GeneTx Biotherapeutics LLC (GeneTx) for the treatment of Angelman syndrome, a debilitating and rare neurogenetic disorder caused by loss-of-function of the maternally inherited allele of the UBE3A gene. In July 2022, the Company executed its option to acquire GeneTx as further described in Note 12;</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:4.5pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">UX701 is an adeno-associated virus 9, (AAV9) gene therapy designed to deliver stable expression of a truncated version of the ATP7B copper transporter following a single intravenous infusion to improve copper distribution and excretion from the body and reverse pathological findings of Wilson liver disease; and</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:4.5pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">UX053 is a messenger RNA (mRNA) product candidate designed for the treatment of patients with Glycogen Storage Disease Type III (GSDIII), a disease caused by a glycogen debranching enzyme (AGL) deficiency that results in glycogen accumulation in the liver and muscle. </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">The Company has sustained operating losses and expects such annual losses to continue over the next several years. The Company’s ultimate success depends on the outcome of its research and development and commercialization activities, for which it expects to incur additional losses in the future. Management recognizes that the Company will likely need to raise additional capital to fully implement its business plans. Through June 30, 2022, the Company has relied primarily on its sale of equity securities, its revenues from commercial products, its sale of future royalties, and strategic collaboration arrangements to finance its operations.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">The Company will likely raise additional capital through the issuance of equity, borrowings, or strategic alliances with partner companies. However, if such financing is not available at adequate levels, the Company would need to reevaluate its operating plans.</span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with GAAP. The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, income taxes, stock-based compensation, revenue recognition, and the liability related to the sale of future royalties. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"> </span></p>
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	159868000
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	290875000
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	517000
CY2021Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	10000000
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2331000
CY2021Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2001000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	162716000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	302876000
CY2022Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	693901000
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	1001451000
CY2022Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	685486000
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	36000
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8038000
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	677484000
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	969592000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1288000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	968309000
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	16189000
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	10504000
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4890000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5727000
CY2022Q2	us-gaap	Inventory Net InventoryNet	21079000
CY2021Q4	us-gaap	Inventory Net InventoryNet	16231000
CY2022Q2	rare	Research Clinical Study And Manufacturing Expenses ResearchClinicalStudyAndManufacturingExpenses	67743000
CY2021Q4	rare	Research Clinical Study And Manufacturing Expenses ResearchClinicalStudyAndManufacturingExpenses	40880000
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	47913000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	62591000
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	54699000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	42084000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	170355000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	145555000
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	89343000
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	86975000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	169278000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	186370000
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	89343000
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	86975000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	169278000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	186370000
CY2021	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties And Capitalized To Property Plant And Equipment NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyaltiesAndCapitalizedToPropertyPlantAndEquipment	34072000
CY2021Q4	rare	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	351786000
	rare	Non Cash Collaboration Royalty Revenue NonCashCollaborationRoyaltyRevenue	10261000
	rare	Non Cash Interest Expense On Liability Related To Sale Of Future Royalties And Capitalized To Property Plant And Equipment NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyaltiesAndCapitalizedToPropertyPlantAndEquipment	17417000
CY2022Q2	rare	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	358942000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	9076000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	66568000
	rare	Contract With Customer Assets Liability Additions During Period ContractWithCustomerAssetsLiabilityAdditionsDuringPeriod	89000
	rare	Contract With Customer Assets Liability Additions During Period ContractWithCustomerAssetsLiabilityAdditionsDuringPeriod	2050000
	rare	Contract With Customer Assets Liability Deductions During Period ContractWithCustomerAssetsLiabilityDeductionsDuringPeriod	-4728000
	rare	Contract With Customer Assets Liability Deductions During Period ContractWithCustomerAssetsLiabilityDeductionsDuringPeriod	-64706000
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4437000
CY2021Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3912000
CY2022Q2	rare	Percentage Of Gross Accounts Receivable Balance PercentageOfGrossAccountsReceivableBalance	0.54
CY2021Q4	rare	Percentage Of Gross Accounts Receivable Balance PercentageOfGrossAccountsReceivableBalance	0.71
	rare	Percentage Of Gross Accounts Receivables From Different Customer PercentageOfGrossAccountsReceivablesFromDifferentCustomer	0.14
CY2021	rare	Percentage Of Gross Accounts Receivables From Different Customer PercentageOfGrossAccountsReceivablesFromDifferentCustomer	0
CY2020Q4	rare	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	335665000
CY2021	rare	Non Cash Collaboration Royalty Revenue NonCashCollaborationRoyaltyRevenue	17951000
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	35865000
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27142000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	65252000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	51440000
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11996505
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8500068
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10687358
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8292032
	rare	Stock Issued During Period Shares At Market Offering StockIssuedDuringPeriodSharesAtMarketOffering	1050372
	rare	Proceeds From Issuance Of Common Stock At Market Offering ProceedsFromIssuanceOfCommonStockAtMarketOffering	78900000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-912000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-121000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-8002000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1283000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8914000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1404000

Files In Submission

Name	View Source	Status
0000950170-22-013411-index-headers.html	Edgar Link	pending
0000950170-22-013411-index.html	Edgar Link	pending
0000950170-22-013411.txt	Edgar Link	pending
0000950170-22-013411-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img215004588_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
rare-20220630.htm	Edgar Link	pending
rare-20220630.xsd	Edgar Link	pending
rare-20220630_cal.xml	Edgar Link	unprocessable
rare-20220630_def.xml	Edgar Link	unprocessable
rare-20220630_htm.xml	Edgar Link	completed
rare-20220630_lab.xml	Edgar Link	unprocessable
rare-20220630_pre.xml	Edgar Link	unprocessable
rare-ex10_1.htm	Edgar Link	pending
rare-ex10_2.htm	Edgar Link	pending
rare-ex31_1.htm	Edgar Link	pending
rare-ex31_2.htm	Edgar Link	pending
rare-ex32_1.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RARE
Ultragenyx Pharmaceutical Inc. Stock $rare

2022 Q3 Form 10-Q Financial Statement

#000095017022013411 Filed on July 29, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RARE Ultragenyx Pharmaceutical Inc. Stock $rare

2022 Q3 Form 10-Q Financial Statement

#000095017022013411 Filed on July 29, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RARE
Ultragenyx Pharmaceutical Inc. Stock $rare